Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7241
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity? ; day:18 ; month:12 ; year:2020 ; pages:1-8
Cardiovascular drugs and therapy ; (18.12.2020), 1-8
- Urheber
-
Tscharre, Maximilian
Wadowski, Patricia P.
Weikert, Constantin
Pultar, Joseph
Eichelberger, Beate
Panzer, Simon
Gremmel, Thomas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10557-020-07128-0
- URN
-
urn:nbn:de:101:1-2021012417575795991945
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tscharre, Maximilian
- Wadowski, Patricia P.
- Weikert, Constantin
- Pultar, Joseph
- Eichelberger, Beate
- Panzer, Simon
- Gremmel, Thomas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
![Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy